CANNABIS Key Strategic Relationships Developed D
Post# of 42157
(Total Views: 90)
Posted On: 10/23/2018 12:54:17 PM
CANNABIS Key Strategic Relationships Developed
During the reporting period, the Group has established many strategic partnerships nationally and internationally.
In December 2017, the Group entered into a binding agreement with AFFINITY ENERGY AND HEALTH LIMITED (ASX: AEB previously known as Algae Tec Ltd) to supply them with genetics from Medical Cannabis Limited’s seedbank. The agreement allows them to utilise MCL’s cannabis genetics to cultivate, process, research and manufacture cannabinoid products for veterinary purposes. AEB is a specialist producer focused on key algae-based nutraceutical, animal and aquaculture and the medical marijuana markets. Algae is produced from the Company’s state-of-the-art growing facility in Atlanta which produces multiple high-demand species to service both the growing nutraceutical and aqua feed markets. AEB has recently applied its industry-leading growing technology to the production of medicinal cannabis through partnerships in Uruguay for the rapidly expanding cannabis market.
In January 2018 the company, through its subsidiary Vitacann Pty Ltd, entered into an exclusive 50/50 Joint venture partnership with the Canadian Canntab Therapeutics company which has developed a patent pending Cannabis GMP Pharmaceutical Grade Extended Release (XR) pill. The joint venture is to market and sell the CanntabTM proprietary products in Australia with a first right to distribute throughout Asia. VitaCann and CannTab will work towards having Canntab’s tablets formally approved for sale in Australia and to export to Asia. Pursuant to recent and evolving legislation in Australia, the Canntab product should qualify for approval, as it should meet all the standard medical requirements that would be expected by the medical industry. The Canntab - VitaCann JV has intellectual property licensed by Canntab, with access now to MCL’s Australian Cannabis strains, and six filed patents protecting the Extended Release Tablets™ (XR). Canntab’s proprietary extended release tablets makes it easier for doctors and patients to manage dosage. They’re easier to take, largely eliminates social stigma, and do not have many of the potential adverse side effects of smoking marijuana.
In February 2018, the Group through its subsidiary Medical Cannabis Research Group entered into a sponsored research agreement with the Technion Research and Development Foundation Ltd (TRDFor Technion). The research is led by Professor Dedi Meri from the faculty of biology. The overall objective of the study is to identify specific Cannabis compounds that can be used in clinical trials as a treatment for auto-immune disease focusing initially on Multiple Sclerosis (MS). In this work, the team of researchers at TRDF aims to elucidate the immunoregulatory properties of phytocannabinoids and terpenes in MS, as well as further investigate Cannabis’ mechanisms of action in these areas. This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimize Cannabis treatment options and efforts toward the creation of personalised medicine for MS patients.
In June 2018, the Company entered into an agreement to acquire Medcan Australia, a company that is fully licensed by the Office of Drug Control to cultivate, produce, manufacture, import and export, medical cannabis products. The company is currently completing the fit out of a highly secure state-of-the-art production and manufacturing facility with capacity to grow up to 6500kg of dried flower per annum. It is anticipated that this facility will be fully operational in early 2019.
https://www.queenslandbauxite.com/
New listing within 3 weeks, around 15 november.
iHub NewsWire
During the reporting period, the Group has established many strategic partnerships nationally and internationally.
In December 2017, the Group entered into a binding agreement with AFFINITY ENERGY AND HEALTH LIMITED (ASX: AEB previously known as Algae Tec Ltd) to supply them with genetics from Medical Cannabis Limited’s seedbank. The agreement allows them to utilise MCL’s cannabis genetics to cultivate, process, research and manufacture cannabinoid products for veterinary purposes. AEB is a specialist producer focused on key algae-based nutraceutical, animal and aquaculture and the medical marijuana markets. Algae is produced from the Company’s state-of-the-art growing facility in Atlanta which produces multiple high-demand species to service both the growing nutraceutical and aqua feed markets. AEB has recently applied its industry-leading growing technology to the production of medicinal cannabis through partnerships in Uruguay for the rapidly expanding cannabis market.
In January 2018 the company, through its subsidiary Vitacann Pty Ltd, entered into an exclusive 50/50 Joint venture partnership with the Canadian Canntab Therapeutics company which has developed a patent pending Cannabis GMP Pharmaceutical Grade Extended Release (XR) pill. The joint venture is to market and sell the CanntabTM proprietary products in Australia with a first right to distribute throughout Asia. VitaCann and CannTab will work towards having Canntab’s tablets formally approved for sale in Australia and to export to Asia. Pursuant to recent and evolving legislation in Australia, the Canntab product should qualify for approval, as it should meet all the standard medical requirements that would be expected by the medical industry. The Canntab - VitaCann JV has intellectual property licensed by Canntab, with access now to MCL’s Australian Cannabis strains, and six filed patents protecting the Extended Release Tablets™ (XR). Canntab’s proprietary extended release tablets makes it easier for doctors and patients to manage dosage. They’re easier to take, largely eliminates social stigma, and do not have many of the potential adverse side effects of smoking marijuana.
In February 2018, the Group through its subsidiary Medical Cannabis Research Group entered into a sponsored research agreement with the Technion Research and Development Foundation Ltd (TRDFor Technion). The research is led by Professor Dedi Meri from the faculty of biology. The overall objective of the study is to identify specific Cannabis compounds that can be used in clinical trials as a treatment for auto-immune disease focusing initially on Multiple Sclerosis (MS). In this work, the team of researchers at TRDF aims to elucidate the immunoregulatory properties of phytocannabinoids and terpenes in MS, as well as further investigate Cannabis’ mechanisms of action in these areas. This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimize Cannabis treatment options and efforts toward the creation of personalised medicine for MS patients.
In June 2018, the Company entered into an agreement to acquire Medcan Australia, a company that is fully licensed by the Office of Drug Control to cultivate, produce, manufacture, import and export, medical cannabis products. The company is currently completing the fit out of a highly secure state-of-the-art production and manufacturing facility with capacity to grow up to 6500kg of dried flower per annum. It is anticipated that this facility will be fully operational in early 2019.
https://www.queenslandbauxite.com/
New listing within 3 weeks, around 15 november.
iHub NewsWire
(0)
(0)
Robert
Scroll down for more posts ▼